Liver cancer combo trial stops early – too few patients to draw conclusions
NCT ID NCT04050462
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This phase II trial tested whether adding either BMS-986253 or cabiralizumab to the immunotherapy nivolumab could shrink tumors better than nivolumab alone in people with advanced liver cancer. The study planned for 75 participants but was terminated after only 13 enrolled. Because it stopped early, we cannot know if either combination works better than the standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (a cancer immunotherapy) combined with either BMS-986253 or cabiralizumab
What this could lead to
If successful, this could point toward a more effective combination treatment for advanced liver cancer that is not curable with current options.
What could go wrong
The trial was terminated early with only 13 participants, so results are very limited. It is unclear if the combinations are safe or effective, and they may cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.